Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Gural

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
BMC Medicine|December 2, 2014
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case seriesRoei D Mazor, Mirra Manevich-Mazor, Anat Kesler, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
Genes & Development|March 5, 2008
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activityXinyang Zhao, Vladimir Jankovic, Alexander Gural, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Pediatric Blood & Cancer|July 3, 2019
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood LeukemiaSarah Elitzur, Nira Arad-Cohen, Shlomit Barzilai-Birenboim, et al.
Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.
Science (New York, N.Y.)|July 19, 2011
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylationLan Wang, Alexander Gural, Xiao-Jian Sun, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
BMC Medicine|December 2, 2014
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case seriesRoei D Mazor, Mirra Manevich-Mazor, Anat Kesler, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
Genes & Development|March 5, 2008
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activityXinyang Zhao, Vladimir Jankovic, Alexander Gural, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Pediatric Blood & Cancer|July 3, 2019
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood LeukemiaSarah Elitzur, Nira Arad-Cohen, Shlomit Barzilai-Birenboim, et al.
Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.
Science (New York, N.Y.)|July 19, 2011
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylationLan Wang, Alexander Gural, Xiao-Jian Sun, et al.
Pageof 4